India-China combine for subcutaneously injected PD-L1 inhibitor takes wings, with Glenmark set to take Alphamab/3D Med’s envafolimab to key emerging markets, widening access for patients.

The National Health Service in England says it will be the first health system in the world to roll out a subcutaneously administered formulation of Tecentriq, after the UK MHRA became the first drug regulator to approve the product.

Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.

Beam Therapeutics also announced that it dosed the first patient in its Phase I/II sickle cell disease trial; Vyne stepped into the increasingly competitive vitiligo space, while Tracon moved further into sarcomas in its checkpoint inhibitor program, and Telix started a small trial of its drug in brain cancer.